Merck to present Phase 3 oncology data at ESMO 2026 congress
Tweet Send to a Friend
Merck (NYSE: MRK) announced it will present first-time results from three pivotal Phase 3 clinical trials during Presidential Symposia at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




